PRP - Platelet Rich Plasma for Diminished Ovarian Reserve (DOR)

Phase-Based Progress Estimates
Diminished Ovarian Reserve (DOR)+1 More
PRP - Platelet Rich Plasma - Procedure
18 - 65
What conditions do you have?

Study Summary

This trial will test whether Platelet Rich Plasma (PRP) can improve ovarian reserve in women with poor ovarian reserve. Women will be randomly assigned to treatment with either PRP or Platelet Poor Plasma (PPP).

Eligible Conditions
  • Diminished Ovarian Reserve (DOR)
  • Diminished Ovarian Reserve Due to Advanced Maternal Age

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 8 weeks

4 weeks
Antral Follicle Count
6 weeks
Embryo Transfer
Embryos Produced
8 weeks

Trial Safety

Trial Design

2 Treatment Groups

PRP group
1 of 2
PPP group
1 of 2
Experimental Treatment
Non-Treatment Group

90 Total Participants · 2 Treatment Groups

Primary Treatment: PRP - Platelet Rich Plasma · Has Placebo Group · N/A

PRP group
Experimental Group · 1 Intervention: PRP - Platelet Rich Plasma · Intervention Types: Procedure
PPP group
PlaceboComparator Group · 1 Intervention: PPP - Platelet Poor Plasma · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks

Who is running the clinical trial?

Center for Human ReproductionLead Sponsor
13 Previous Clinical Trials
1,083 Total Patients Enrolled
1 Trials studying Diminished Ovarian Reserve (DOR)
66 Patients Enrolled for Diminished Ovarian Reserve (DOR)
David H Barad, MDPrincipal InvestigatorCenter for Human Reproduction
1 Previous Clinical Trials
30 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · Female Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New Jersey28.6%
New York28.6%
How old are they?
18 - 65100.0%
What site did they apply to?
Center for Human Reproduction100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%